Reported Earlier, Innovent's Phase 3 DREAMS-2 Trial Shows Mazdutide's Superiority Over Dulaglutide In Chinese Type 2 Diabetes Patients At EASD 2024
Reported Earlier, Innovent's Phase 3 DREAMS-2 Trial Shows Mazdutide's Superiority Over Dulaglutide In Chinese Type 2 Diabetes Patients At EASD 2024
據報道，英飛凌的第三階段DREAMS-2臨床試驗顯示，在2024年歐洲糖尿病聯盟年會上，馬茲度肽在中國2型糖尿病患者中比度拉古肽更優越。
The study results demonstrated the superiority of mazdutide to dulaglutide in both glycemic control and body weight reduction in Chinese participants with T2D. Additionally, mazdutide treatment improved several cardiometabolic risk factors, including blood pressure, lipids, serum uric acid and liver enzymes. Detailed results will be published in peer-reviewed journals.
研究結果表明，對於患有T2D的中國受試者，在血糖控制和減輕體重方面，mazdutide優於度拉魯肽。此外，mazdutide治療改善了多種心臟代謝風險因素，包括血壓、血脂、血清尿酸和肝酶。詳細結果將在同行評審期刊上發表。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。